

Arch Therapeutics, Inc.  
Form 424B3  
January 13, 2015

**Filed Pursuant to Rule 424(b)(3)**

**Registration No. 333-194745**

**PROSPECTUS SUPPLEMENT NO. 10 DATED JANUARY 13, 2015**

**TO**

**PROSPECTUS DATED JULY 2, 2014**

**(AS SUPPLEMENTED)**

**ARCH THERAPEUTICS, INC.**

**PROSPECTUS**

**Up to 45,600,000 Shares of Common Stock**

This Prospectus Supplement No. 10 supplements the prospectus of Arch Therapeutics, Inc. (“the “Company”, “we”, “us”, or “our”) dated July 2, 2014 (as supplemented to date, the “Prospectus”) with the following attached document which we filed with the Securities and Exchange Commission on January 13, 2015:

- A. Our Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2015

This Prospectus Supplement No. 10 should be read in conjunction with the Prospectus, which is required to be delivered with this Prospectus Supplement. This prospectus supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.

**Investing in our common stock involves a high degree of risk. Before making any investment in our common stock, you should carefully consider the risk factors for our common stock, which are described in the Prospectus, as amended or supplemented.**

**You should rely only on the information contained in the Prospectus, as supplemented or amended by this Prospectus Supplement No. 10 and any other prospectus supplement or amendment thereto. We have not authorized anyone to provide you with different information.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this Prospectus Supplement No. 10 is January 13, 2015

---

## **INDEX TO FILINGS**

The Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2015

**Annex**  
**A**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 13, 2015**

**ARCH THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**                                **000-54986**    **46-0524102**  
(State or other jurisdiction    (Commission    (I.R.S. Employer  
of incorporation)                File Number)    Identification No.)

**20 William Street, Suite 270**  
**Wellesley, Massachusetts**                **02481**  
(Address of principal executive offices)    (Zip Code)

Registrant's telephone number, including area code: **(617) 431-2313**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

“Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: Arch Therapeutics, Inc. - Form 424B3

“Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

“Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On January 13, 2015, Arch Therapeutics, Inc. (the “Company”) issued a press release announcing further positive preclinical test results of its AC5 Surgical Hemostatic Device™ in standardized tests for irritation potential. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibit**

(d) Exhibits

**Exhibit Description**

99.1 Press Release issued by Arch Therapeutics, Inc. on January 13, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARCH THERAPEUTICS, INC.**

Dated: January 13, 2015 By: /s/ Terrence W. Norchi, M.D.  
Name: Terrence W. Norchi, M.D.  
Title: President, Chief Executive  
Officer

EXHIBIT INDEX

**Exhibit Description**

99.1 Press Release issued by Arch Therapeutics, Inc. on January 13, 2015

## **Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device™ in Preclinical Safety Study**

*AC5™ Safety Further Supported; Non-Irritant in Animal Testing*

**WELLESLEY, MA – January 13, 2015**-- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™, obtained positive results when AC5™ was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization’s (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

In this standard three-day *in vivo* rabbit model study, AC5 tested in relevant amounts was well tolerated, gave a zero (0) irritation score and was classified as a negligible irritant using a standardized scoring system. A device in this study can be classified and scored as negligible (0.0-0.4), slight (0.5-1.9), moderate (2.0-4.9) or severe (5.0-8.0). Results from this biocompatibility safety study indicate that AC5’s peptide structure and mechanism of action, which is based on the formation of a local physical-mechanical barrier at the wound site, does not promote application site erythema or edema, which are indices of irritation. This study represents further data supporting the absence of toxicity for AC5, and represents an important step in demonstrating biocompatibility of AC5.

Arch Therapeutics President and CEO Terrence Norchi, MD, stated, “These promising results underscore our positive expectations for AC5. We look forward to additional studies with AC5 that indicate its potential value in terms of safety, efficacy and user-friendliness.”

### **About Arch Therapeutics, Inc.**

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Find out more at [www.archtherapeutics.com](http://www.archtherapeutics.com).

### **Notice Regarding Forward-Looking Statements**

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act



of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at [www.sec.gov](http://www.sec.gov).

On Behalf of the Board,  
Terrence W. Norchi, MD  
Arch Therapeutics, Inc.

**Contact:**

ARTH Investor Relations  
Toll Free: +1-855-340-ARTH (2784) (US and Canada)  
Email: [investors@archtherapeutics.com](mailto:investors@archtherapeutics.com)  
Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

Or

Richard Davis

Chief Financial Officer

Arch Therapeutics, Inc.

Phone: 617-431-2308

Email: [rdavis@archtherapeutics.com](mailto:rdavis@archtherapeutics.com)

Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)